In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients

Journal of Clinical InvestigationLi S, Sarangarajan R, Jun T, et al. | October 05, 2021


A significant reduction in in-hospital mortality was observed among COVID-19–positive African American patients in correlation with in-hospital use of angiotensin receptor blockers.

  • Between February 24 and May 31, 2020, a total of 6,218 patients were identified who were admitted with COVID-19 in Mount Sinai hospitals in New York City; 1,138 of these patients (18.3%) received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACE-I/ARB).

  • A multivariate logistic regression model revealed independent correlation of ACE-I/ARB use with a lowered risk of in-hospital mortality in the entire population.

  • The African American population had improved mortality in correlation with in-hospital use of ACE-I/ARB, but not with outpatient use.

  • Separate analysis of each medication class revealed significant correlation of ARB in-hospital use with reduced in-hospital mortality in the African American population, whereas there appeared no influence of ACE-I use on mortality in any population.

Read the full article on Journal of Clinical Investigation